Alnylam Pharmaceuticals (ALNY) is trading up at $224.47 (+0.29%) on NASDAQ, as of the latest quote. It is a Nasdaq-100 constituent in the Health Care sector.
Alnylam Pharmaceuticals revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $47.2M | $89.9M | $74.9M | $219.8M | $492.9M | $844.3M | $1.04B | $1.83B | $2.25B | $3.71B |
| Growth (year over year) | — | +90.7% | −16.7% | +193.4% | +124.3% | +71.3% | +22.9% | +76.2% | +23.0% | +65.2% |
| Gross profit | — | $89.9M | $73.1M | $194.7M | $418.7M | $729.3M | $897.2M | $1.56B | $1.94B | $3.04B |
| Gross margin | — | 100.0% | 97.6% | 88.6% | 84.9% | 86.4% | 86.5% | 85.3% | 86.4% | 81.8% |
| Operating income | −$424.6M | −$500.1M | −$814.7M | −$939.4M | −$828.4M | −$708.7M | −$785.1M | −$282.2M | −$176.9M | $501.6M |
| Operating margin | −900.3% | −556.2% | −1087.6% | −427.5% | −168.1% | −83.9% | −75.7% | −15.4% | −7.9% | 13.5% |
| Net income | −$410.1M | −$490.9M | −$761.5M | −$886.1M | −$858.3M | −$852.8M | −$1.13B | −$440.2M | −$278.2M | $313.7M |
| Net margin | −869.6% | −545.9% | −1016.6% | −403.2% | −174.1% | −101.0% | −109.0% | −24.1% | −12.4% | 8.4% |
| EPS (diluted) | −$4.79 | −$5.42 | −$7.57 | −$8.11 | −$7.46 | −$7.20 | −$9.30 | −$3.52 | −$2.18 | $2.33 |
| Balance sheet | ||||||||||
| Cash and equivalents | $193.6M | $645.4M | $420.1M | $547.2M | $496.6M | $820.0M | $866.4M | $812.7M | $966.4M | $1.66B |
| Total assets | $1.26B | $1.99B | $1.57B | $2.40B | $3.41B | $3.64B | $3.55B | $3.83B | $4.24B | $4.97B |
| Total liabilities | $342.6M | $228.3M | $272.8M | $956.4M | $2.39B | $3.06B | $3.70B | $4.05B | $4.17B | $4.18B |
| Long-term debt | — | — | — | — | $191.3M | $675.7M | — | — | — | — |
| Shareholders' equity | $920.2M | $1.77B | $1.30B | $1.44B | $1.02B | $588.2M | −$158.2M | −$220.6M | $67.1M | $789.2M |
| Cash flow | ||||||||||
| Operating cash flow | −$307.7M | −$382.8M | −$562.6M | −$278.4M | −$615.0M | −$641.7M | −$541.3M | $104.2M | −$8.31M | $524.1M |
| Capital expenditure | $64.6M | $104.2M | $126.9M | $140.2M | $70.4M | $76.4M | $72.1M | $62.2M | $34.3M | $58.7M |
| Free cash flow | −$372.3M | −$487.0M | −$689.5M | −$418.6M | −$685.3M | −$718.1M | −$613.3M | $41.9M | −$42.6M | $465.4M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26†Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $500.9M | $593.2M | $594.2M | $773.7M | $1.25B | $1.10B | $1.17B | $1.29B |
| Growth (year over year) | −33.3% | +34.9% | +20.2% | +17.3% | +149.3% | +84.9% | +96.4% | +66.9% |
| Gross profit | $418.9M | $490.5M | $524.0M | $631.7M | $1.05B | $829.3M | $959.7M | $992.7M |
| Gross margin | 83.6% | 82.7% | 88.2% | 81.6% | 84.2% | 75.6% | 82.2% | 76.9% |
| Operating income | −$76.9M | −$105.2M | $18.1M | −$16.2M | $368.0M | $131.7M | $268.6M | $231.4M |
| Operating margin | −15.4% | −17.7% | 3.0% | −2.1% | 29.5% | 12.0% | 23.0% | 17.9% |
| Net income | −$111.6M | −$83.8M | −$18.3M | −$72.2M | $251.1M | $153.1M | $206.0M | $164.5M |
| Net margin | −22.3% | −14.1% | −3.1% | −9.3% | 20.1% | 14.0% | 17.6% | 12.7% |
| EPS (diluted) | −$0.87 | −$0.66 | −$0.14 | −$0.55 | $1.84 | $1.18 | $1.50 | $1.21 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.10B | $966.4M | $1.02B | $1.11B | $1.49B | $1.66B | — | $1.71B |
| Total assets | $4.21B | $4.24B | $4.21B | $4.57B | $4.85B | $4.97B | — | $5.56B |
| Total liabilities | $4.17B | $4.17B | $4.10B | $4.32B | $4.62B | $4.18B | — | $4.20B |
| Shareholders' equity | $32.4M | $67.1M | $426.1M | $555.3M | $233.9M | $789.2M | $1.08B | $1.35B |
| Cash flow | ||||||||
| Operating cash flow | $43.7M | −$94.7M | −$118.3M | $127.8M | $351.0M | $163.6M | — | — |
| Capital expenditure | $4.19M | $9.09M | $8.97M | $14.3M | $12.1M | $23.3M | — | — |
| Free cash flow | $39.5M | −$103.8M | −$127.3M | $113.5M | $338.9M | $140.3M | — | — |
From Alnylam Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Source: Wikipedia — Alnylam Pharmaceuticals
- Headquarters
- Cambridge, Massachusetts From SEC filings, Oct 2026
Recent News (2)
More Health Care stocks
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- AMGN Amgen
- BAX Baxter International
- BDX Becton Dickinson
- BIIB Biogen